1.23
price up icon3.36%   0.04
after-market Dopo l'orario di chiusura: 1.24 0.01 +0.81%
loading
Precedente Chiudi:
$1.19
Aprire:
$1.21
Volume 24 ore:
377.71K
Relative Volume:
0.31
Capitalizzazione di mercato:
$9.92M
Reddito:
-
Utile/perdita netta:
$-16.63M
Rapporto P/E:
-2.8605
EPS:
-0.43
Flusso di cassa netto:
$-21.84M
1 W Prestazione:
+3.36%
1M Prestazione:
+13.89%
6M Prestazione:
-44.84%
1 anno Prestazione:
-78.42%
Intervallo 1D:
Value
$1.155
$1.24
Intervallo di 1 settimana:
Value
$1.155
$1.32
Portata 52W:
Value
$0.7233
$6.5985

Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile

Name
Nome
Brainstorm Cell Therapeutics Inc
Name
Telefono
201-488-0460
Name
Indirizzo
1325 AVENUE OF AMERICAS, NEW YORK, NY
Name
Dipendente
29
Name
Cinguettio
@BrainStormCell
Name
Prossima data di guadagno
2024-11-05
Name
Ultimi documenti SEC
Name
BCLI's Discussions on Twitter

Confronta BCLI con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BCLI
Brainstorm Cell Therapeutics Inc
1.23 9.92M 0 -16.63M -21.84M -0.43
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
450.27 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
522.27 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.00 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
568.06 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
266.80 28.51B 3.81B -644.79M -669.77M -6.24

Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-02-04 Aggiornamento Maxim Group Hold → Buy
2020-11-17 Downgrade Maxim Group Buy → Hold
2016-12-19 Reiterato Maxim Group Buy
2015-12-22 Reiterato Maxim Group Buy

Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie

pulisher
Jun 17, 2025

Autologous Cell Therapy Market Size, Global Trends And Forecast to 2033 - Straits Research

Jun 17, 2025
pulisher
Jun 16, 2025

Brainstorm Cell's NurOwn Study Data Shows 90% Survival Rate In ALS Patients, Stock Up In Pre-Market - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Encouraging Survival Data Revealed for BrainStorm's NurOwn in ALS Study (BCLI) | BCLI Stock News - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn® - PR Newswire

Jun 16, 2025
pulisher
Jun 14, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Sell at Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Jun 12, 2025
pulisher
Jun 06, 2025

Brainstorm taps Minaris to produce NurOwn for Phase 3b trial - ALS News Today

Jun 06, 2025
pulisher
Jun 05, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Brainstorm Cell Therapeutics Inc.(BCLI) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Jun 05, 2025
pulisher
Jun 03, 2025

Neuromuscular Disease Therapeutics Market Growth Driven - openPR.com

Jun 03, 2025
pulisher
Jun 01, 2025

5 Best Stem Cell Companies to Invest In (June 2025) - Securities.io

Jun 01, 2025
pulisher
May 30, 2025

What is Zacks Small Cap’s Estimate for BCLI FY2025 Earnings? - Defense World

May 30, 2025
pulisher
May 29, 2025

Q2 Earnings Estimate for BCLI Issued By Zacks Small Cap - Defense World

May 29, 2025
pulisher
May 28, 2025

BCLI: Receives Regulatory Clearance to Initiate Phase 3b ALS Trial… - MSN

May 28, 2025
pulisher
May 28, 2025

BrainStorm Cell Therapeutics and Minaris partner on manufacturing NurOwn for trial - Yahoo Finance

May 28, 2025
pulisher
May 27, 2025

BrainStorm partners with Minaris for ALS therapy trial By Investing.com - Investing.com South Africa

May 27, 2025
pulisher
May 27, 2025

BrainStorm partners with Minaris for ALS therapy trial - Investing.com Australia

May 27, 2025
pulisher
May 27, 2025

BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for Nu - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BrainStorm Cell Therapeutics (BCLI) Partners with Minaris for NurOwn Manufacturing | BCLI Stock News - GuruFocus

May 27, 2025
pulisher
May 27, 2025

BrainStorm Accelerates NurOwn ALS Treatment Development Through Major Manufacturing Deal with Minaris - Stock Titan

May 27, 2025
pulisher
May 26, 2025

INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell Lawsuit – BCLI - ACCESS Newswire

May 26, 2025
pulisher
May 23, 2025

FDA clears Phase 3b trial of NurOwn for ALS - ALS News Today

May 23, 2025
pulisher
May 22, 2025

Gene And Cell Therapies Targeting Cns Disorders Market in 2025 - openPR.com

May 22, 2025
pulisher
May 22, 2025

Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews

May 22, 2025
pulisher
May 21, 2025

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - Defense World

May 21, 2025
pulisher
May 20, 2025

Brainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plans - MSN

May 20, 2025
pulisher
May 20, 2025

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 20, 2025
pulisher
May 20, 2025

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

May 20, 2025
pulisher
May 20, 2025

What Did We Note About Insider Trading At Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI)? - Stocksregister

May 20, 2025
pulisher
May 20, 2025

FDA grants clearance to BrainStorm’s Phase IIIb trial of ALS treatment - Yahoo Finance

May 20, 2025
pulisher
May 19, 2025

Brainstorm Cell Therapeutics Reports Q1 2025 Financials - TipRanks

May 19, 2025
pulisher
May 19, 2025

BrainStorm advances ALS treatment with FDA trial nod By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

BrainStorm advances ALS treatment with FDA trial nod - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Sector Update: Health Care Stocks Advance Monday Afternoon - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Top Midday Gainers - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BrainStorm (BCLI) Options Delisting Announced | BCLI Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Earnings call transcript: BrainStorm Cell Therapeutics Q1 2025 sees stock surge after trial updates - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

Micro Cap Bid Up Aggressively On FDA Clearance Announcement - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

Transcript : Brainstorm Cell Therapeutics Inc., Q1 2025 Earnings Call, May 19, 2025 - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

BrainStorm (BCLI) Receives FDA Green Light for NurOwn Phase 3b A - GuruFocus

May 19, 2025
pulisher
May 19, 2025

BrainStorm Cleared by FDA to Begin Phase 3b Trial of NurOwn for ALS - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Breaking ALS Treatment News: FDA Gives Green Light to BrainStorm's Crucial Phase 3b NurOwn Trial - Stock Titan

May 19, 2025
pulisher
May 16, 2025

SEC Form DEFA14A filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

May 16, 2025
pulisher
May 16, 2025

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - StreetInsider

May 16, 2025
pulisher
May 16, 2025

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - PR Newswire

May 16, 2025
pulisher
May 16, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - The Malaysian Reserve

May 16, 2025
pulisher
May 15, 2025

SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

May 15, 2025
pulisher
May 15, 2025

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025
pulisher
May 15, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Rele - GuruFocus

May 15, 2025
pulisher
May 15, 2025

BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan

May 15, 2025
pulisher
May 15, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 – Company AnnouncementFT.com - Financial Times

May 15, 2025

Brainstorm Cell Therapeutics Inc Azioni (BCLI) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Brainstorm Cell Therapeutics Inc Azioni (BCLI) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Lebovits Chaim
President & CEO
Sep 30 '24
Buy
0.23
22,000
5,016
1,186,865
Dagher Ibrahim B.
Chief Medical Officer
Jul 19 '24
Sale
0.35
63,000
22,069
0
$20.74
price up icon 0.29%
$36.14
price up icon 2.09%
$20.92
price up icon 2.60%
$105.90
price up icon 0.46%
$105.09
price up icon 2.02%
biotechnology ONC
$266.80
price up icon 3.61%
Capitalizzazione:     |  Volume (24 ore):